Ephedra
What Is Ephedra Used for Today?
What Is the Scientific Evidence for Ephedra?
Dosage
Safety Issues
- Cardiovascular disease, including:
- Enlargement of the prostate
- Diabetes
- Hepatitis
- Myocarditis
- Vasculitis
- Diseases of the nervous system
- Glaucoma
- Hyperthyroidism
- Young children
- Pregnant or nursing women
- People with kidney disease
- People with liver disease
Interactions You Should Know About
- MAO inhibitors : Do not take ephedra.
- Any stimulant drugs (including caffeine): Do not take ephedra except under physician supervision.
References
1 Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes Relat Metab Disord. 1992;16:269-277.
2 Molnar D, Torok K, Erhardt E, et al. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord. 2000;24:1573-1578.
3 Breum L, Pedersen JK, Ahlstrom F, et al. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. Int J Obes Relat Metab Disord. 1994;18:99-103.
4 Boozer CN, Nasser JA, Heymsfield SB, et al. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord. 2001;25:316-324.
5 Norregaard J, Jorgensen S, Mikkelsen KL, et al. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. Clin Pharmacol Ther. 1996;60:679-686.
6 Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes Relat Metab Disord. 1992;16:269-277.
7 Molnar D, Torok K, Erhardt E, et al. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord. 2000;24:1573-1578.
8 Breum L, Pedersen JK, Ahlstrom F, et al. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. Int J Obes Relat Metab Disord. 1994;18:99-103.
9 Boozer CN, Nasser JA, Heymsfield SB, et al. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord. 2001;25:316-324.
10 Norregaard J, Jorgensen S, Mikkelsen KL, et al. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. Clin Pharmacol Ther. 1996;60:679-686.
11 Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res. 1995;3:537S-540S.
12 MedscapeWire. No association between reported adverse events and ephedra when consumed as directed. Available at: http://www.medscape.com/MedscapeWire/2000/0800/medwire.0816.Nol . Accessed August 16, 2000.
13 Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm . 2000;57:963-969.
14 MedscapeWire. No association between reported adverse events and ephedra when consumed as directed. Available at: http://www.medscape.com/MedscapeWire/2000/0800/medwire.0816.Nol . Accessed August 16, 2000.
15 Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med . 2000;343:1833-1838.
16 Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm . 2000;57:963-969.
17 Physicians' Desk Reference For Herbal Medicines . Montvale, NJ: Medical Economics Co; 1998:827.
18 Samenuk D, Link M, Homoud M K, et al. Adverse cardiovascular events temporally associated with Ma Huang, an herbal source of ephedrine. Mayo Clin Proc . 2002;77:12-16.
19 Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord . 2002;26:593-604.
20 Meston CM, Heiman JR. Ephedrine-activated physiological sexual arousal in women. Arch Gen Psychiatry . 1998;55:652-656.
21 Nishiguchi M, Kinoshita H, Higasa K, et al. The false positive reaction of the Triage panel drug-of-abuse by herbal drugs ma-huang (Ephedra sinica Ephedraceae). Nippon Hoigaku Zasshi . 2001;55:331-338.
22 Bruno A, Nolte KB, Chapin J. Stroke associated with ephedrine use. Neurology . 1993;43:1313-1316.
23 Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. J Clin Psychopharmacol. 1997;17:437-439.
24 Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol . 2001;96:1654-1655.
25 Nadir A, Agrawal S, King PD, et al. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol . 1996;91:1436-1438.
26 Zaacks SM, Klein L, Tan CD, et al. Hypersensitivity myocarditis associated with ephedra use J Toxicol Clin Toxicol . 1999;37:485-489.
27 Powell T, Hsu FF, Turk J, Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis . 1998;32:153-159.
28 Lee MK, Cheng BW, Che CT, et al. Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. Toxicol Sci . 2000;56:424-430.
29 Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA . 2003;289:1537-1545.
30 Bent S, Tiedt TN, Odden MC, et al. The relative safety of ephedra compared with other herbal products. Ann Intern Med . 2003;138:468-471.
31 Coffey CS, Steiner D, Baker BA, et al. A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. Int J Obes Relat Metab Disord . 2004 Aug 31. [Epub ahead of print]
32 Meston CM. A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual Dysfunction. J Sex Marital Ther . 2004;30:57-68.
33 Levisky JA, Karch SB, Bowerman DL, et al. False-positive RIA for methamphetamine following ingestion of an ephedra-derived herbal product. J Anal Toxicol . 2003;27(2):123-124.
34 Walton R, Manos GH. Psychosis related to ephedra-containing herbal supplement use. South Med J . 2003;96:718-720.
35 Skoulidis F, Alexander GJ, Davies SE. Ma huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol . 2005;17:581-584.
36 FDA statement on Tenth Circuit's ruling to uphold FDA decision banning dietary supplements containing ephedrine alkaloids. Food and Drug Administration website. Available at: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01434.html . Accessed: October 30, 2007.
37 Sales of supplements containing ephedrine alkaloids (ephedra) prohibited. Food and Drug Administration website. Available at: http://www.fda.gov/oc/initiatives/ephedra/february2004/default.htm . Accessed: October 30, 2007.
38 Chen WL, Tsai TH, Yang CC, Kuo TB. Effects of ephedra on autonomic nervous modulation in healthy young adults. J Ethnopharmacol. 2010;130(3):563-568.
39 Hallas J, Bjerrum L, Støvring H, Andersen M. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol. 2008;168(8):966-973.
Revision Information
- Reviewer: EBSCO CAM Review Board
- Review Date: 07/2012 -
- Update Date: 07/25/2012 -
Digg
Del.icio.us
Yahoo
Google
Newsvine